<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPX</journal-id>
<journal-id journal-id-type="hwp">sptpx</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Pathol</journal-id>
<journal-title>Toxicologic Pathology</journal-title>
<issn pub-type="ppub">0192-6233</issn>
<issn pub-type="epub">1533-1601</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0192623312446527</article-id>
<article-id pub-id-type="publisher-id">10.1177_0192623312446527</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Regular Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gender Differences in Chemical Carcinogenesis in National Toxicology Program 2-Year Bioassays</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kadekar</surname>
<given-names>Sandeep</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312446527">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peddada</surname>
<given-names>Shyamal</given-names>
</name>
<xref ref-type="aff" rid="aff2-0192623312446527">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silins</surname>
<given-names>Ilona</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312446527">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>French</surname>
<given-names>John E.</given-names>
</name>
<xref ref-type="aff" rid="aff2-0192623312446527">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Högberg</surname>
<given-names>Johan</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312446527">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Stenius</surname>
<given-names>Ulla</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312446527">1</xref>
<xref ref-type="corresp" rid="corresp1-0192623312446527"/>
</contrib>
</contrib-group>
<aff id="aff1-0192623312446527">
<label>1</label>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden</aff>
<aff id="aff2-0192623312446527">
<label>2</label>National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA</aff>
<author-notes>
<corresp id="corresp1-0192623312446527">Ulla Stenius, Institute of Environmental Medicine, Karolinska Institutet, Box 210, 17177 Stockholm, Sweden; e-mail: <email>ulla.stenius@ki.se</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>40</volume>
<issue>8</issue>
<fpage>1160</fpage>
<lpage>1168</lpage>
<permissions>
<copyright-statement>© 2012 by The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society of Toxicologic Pathology</copyright-holder>
</permissions>
<abstract>
<p>Differences in cancer incidences between men and women are often explained by either differences in environmental exposures or by influences of sex hormones. However, there are few studies on intrinsic gender differences in susceptibility to chemical carcinogens. We have analyzed the National Toxicology Program (NTP) database for sex differences in rat responses to chemical carcinogens. We found that the odds that male rat bioassays were assigned a higher level of evidence than female rat bioassays was 1.69 (<italic>p</italic> &lt; .001). Of 278 carcinogenic chemicals in the database, 201 (72%) exhibited statistical gender differences (<italic>p</italic> ≤ .05) in at least one nonreproductive organ. One hundred thirty of these 201 chemicals induced gender-specific tumors in male rats and 59 in female rats. Sixty-eight chemicals induced tumors in males but no tumors in females. Less than one third (i.e., 19 chemicals) induced tumors in females but not males. Male-specific tumors included pancreatic and skin tumors, and female-specific tumors included lung tumors. For some tumor sites, these differences in gender susceptibility can be associated with literature data on sex hormone receptor expression. In conclusion, gender-specific tumors were common. The male dominance is in line with recent human data, and the male susceptibility to carcinogens should be further studied.</p>
</abstract>
<kwd-group>
<kwd>NTP</kwd>
<kwd>gender</kwd>
<kwd>2-year bioassay</kwd>
<kwd>tumor</kwd>
<kwd>carcinogens</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0192623312446527">
<title>Introduction</title>
<p>Excluding reproductive organs, cancer incidences are often different in men and women (<xref ref-type="bibr" rid="bibr8-0192623312446527">Cook et al. 2009</xref>; <xref ref-type="bibr" rid="bibr9-0192623312446527">Edgren et al. 2012</xref>). The fact that mammary and prostate cancers are among the most common human cancer types suggests a fundamental influence of sex hormones (c.f. <xref ref-type="bibr" rid="bibr30-0192623312446527">Lin and Giovannucci 2010</xref>). The role of sex hormones in cancer development has been extensively studied (<xref ref-type="bibr" rid="bibr2-0192623312446527">Anderson 2005</xref>; <xref ref-type="bibr" rid="bibr11-0192623312446527">Folkerd and Dowsett 2010</xref>) along with the role of hormonal replacement therapy (<xref ref-type="bibr" rid="bibr46-0192623312446527">Santen et al. 2010</xref>). However, gender differences in response to xenobiotic carcinogens may also contribute. Such differences can often be related to gender differences in exposure to carcinogens in, for example, work places. Lifestyle or nutritional factors may also influence gender-specific responses, as discussed previously (<xref ref-type="bibr" rid="bibr22-0192623312446527">Kirsch-Volders et al. 2010</xref>). Of importance for the present work is that it can be assumed that there are intrinsic differences in susceptibility to xenobiotic carcinogens as, for example, discussed for kidney tumors in male rats (<xref ref-type="bibr" rid="bibr28-0192623312446527">Leavens and Borghoff 2009</xref>) or for human lung tumors (<xref ref-type="bibr" rid="bibr49-0192623312446527">Uppstad et al. 2011</xref>; <xref ref-type="bibr" rid="bibr9-0192623312446527">Edgren et al. 2012</xref>). This aspect of carcinogenesis, as well as gender disparities in general, has been surprisingly little studied (<xref ref-type="bibr" rid="bibr12-0192623312446527">Gochfeld 2007</xref>; <xref ref-type="bibr" rid="bibr8-0192623312446527">Cook et al. 2009</xref>; <xref ref-type="bibr" rid="bibr22-0192623312446527">Kirsch-Volders et al. 2010</xref>; <xref ref-type="bibr" rid="bibr9-0192623312446527">Edgren et al. 2012</xref>).</p>
<p>In an effort to get an overview of a possible gender difference in susceptibility to chemical carcinogens, we have analyzed the results obtained in 2-year bioassays published in the National Toxicology Program (NTP) database.</p>
<p>The relevance of rodent carcinogenesis for humans has been discussed in numerous publications (<xref ref-type="bibr" rid="bibr34-0192623312446527">Maronpot, Flake, and Huff 2004</xref>; <xref ref-type="bibr" rid="bibr3-0192623312446527">Anisimov, Ukraintseva, and Yashin 2005</xref>; <xref ref-type="bibr" rid="bibr17-0192623312446527">Hoenerhoff et al. 2009</xref>). Although relevance has been demonstrated in some cases but not in others, animal models remain important in predicting human risk for carcinogens (<xref ref-type="bibr" rid="bibr18-0192623312446527">Huff 2010</xref>). A recent example is animal data influencing formaldehyde risk assessment (<xref ref-type="bibr" rid="bibr1-0192623312446527">Andersen et al. 2010</xref>). Here, we present rat (mainly Fisher 344) data, which generally are considered more comparable for human cancer than mouse data (<xref ref-type="bibr" rid="bibr49-0192623312446527">Uppstad et al. 2011</xref>). Thus, there is little similarity in the spectrum of spontaneous tumors developed by humans compared with mice and rats, but in contrast to mice and similar to humans, rats develop epithelial tumors more frequently (<xref ref-type="bibr" rid="bibr3-0192623312446527">Anisimov et al. 2005</xref>). Furthermore, in a time window above the female reproductive period, the overall cancer risk is higher in males than in females in both rats and humans (<xref ref-type="bibr" rid="bibr3-0192623312446527">Anisimov, Ukraintseva, and Yashin 2005</xref>; <xref ref-type="bibr" rid="bibr20-0192623312446527">International Agency for Research on Cancer 2010</xref>). It is also crucial to emphasize that cancer epidemiology has inherent weaknesses. These include problems associated with decades of latency periods, problems associated with exposure assessments and the complexity of interacting exposures, dietary differences, and the relative rarity of tumors at a specific site. These weaknesses indicate that, for example, negative epidemiological data for a given chemical and a given tumor site do not necessarily exclude human risks (<xref ref-type="bibr" rid="bibr19-0192623312446527">Huff, Jacobson, and Davis 2008</xref>).</p>
<p>Cancer tests typically employ male and female rats, mimicking lifetime exposure to carcinogens (<xref ref-type="bibr" rid="bibr37-0192623312446527">NTP 2009</xref>). In contrast to practically all human observational studies, exposures, diets and environmental factors are very well controlled. For example, in NTP tests, male and female rats are treated identically, and although doses are not adjusted to give, for example, equal internal dose, doses are adjusted to weight for each sex. Thus, it can be expected that the NTP database is informative concerning fundamental intrinsic aspects of gender differences in chemical carcinogenesis.</p>
<p>We here present an evaluation of NTP chronic bioassays published between 1976 and 2009. Our hypothesis is that carcinogens might interact with sex hormones and that such interactions should be reflected in the NTP database. Such interactions have been suggested by <xref ref-type="bibr" rid="bibr9-0192623312446527">Edgren et al. (2012</xref>) and studied experimentally in, for example, bladder cancer (<xref ref-type="bibr" rid="bibr35-0192623312446527">Miyamoto et al. 2007</xref>). It was assumed that even weak carcinogenic responses might be informative when analyzing gender-specific trends among several bioassays, so we included not only assays with clear evidence and some evidence but also assays with equivocal evidence in most analysis. Of 278 carcinogenic chemicals identified by NTP, 201 (72%) showed gender differences, and we found that males had more tumors. In this presentation, we will focus on commonly affected tumor sites in nonreproductive organs, not on individual chemicals.</p>
</sec>
<sec id="section2-0192623312446527" sec-type="methods">
<title>Methods</title>
<sec id="section3-0192623312446527">
<title>The NTP Database and 2-Year Cancer Bioassays</title>
<p>The list of NTP peer-reviewed technical reports (http://ntp.niehs.nih.gov/) is arranged by report number and includes carcinogenicity conclusions and links to the technical report abstracts, levels of evidence, and results and status reports. Levels of evidence include clear evidence, some evidence, equivocal evidence, and no evidence. Clear evidence is conferred on chemicals that cause dose-related (1) increase of malignant neoplasms, (2) increase of a combination of malignant and benign neoplasms, or (3) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy. Some evidence indicates a chemical-related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence. Equivocal evidence indicates a marginal increase of neoplasms that may be chemically related. No evidence is defined as no chemically related increase in tumors. All assays with results classified as clear evidence, some evidence, and equivocal evidence and with both male and female rats were included. A subset of 477 bioassays included both genders, and 86% of these employed Fisher 344 rats. Bioassays performed in one gender, classified by NTP as an “inadequate experiment,” or with no evidence were excluded. Also excluded were results without statistically significant effects at a specific site. In older studies, some or equivocal evidence does not appear, but these assays were few and do not affect the analysis.</p>
<p>Tumors in the following male and female reproductive organs were not included in the analysis: penis, testis, epididymis, vas deferens, seminal vesicles, ejaculatory ducts, prostate and bulbourethral glands, vulva, clitoral glands, clitoris, vagina, uterus, ovary, fallopian tubes, and mammary glands. Tumors in the tunica vaginalis in scrotum were included as mesotheliomas originating in this tissue may spread to abdominal mesothelium and site of origin was not reported.</p>
</sec>
<sec id="section4-0192623312446527">
<title>Statistical Analysis</title>
<p>We compared the tumor rates of males and females by each organ separately using standard analysis of variance. Since there were several potential differences among various studies, such as year of the study, number of doses used in the study, route of exposure, feed, and so forth, we compared the two sexes after adjusting for these study differences. This was done by nesting sex within study (i.e., chemical). Note that a large number of comparisons are being made when investigating the differences between the sexes with respect to each chemical (i.e., each NTP study) for a given tumor. To deal with multiple comparison issues, we performed the pairwise comparisons only in those cases in which the overall “sex within study” effect was significant at <italic>p</italic> ≤ .05. Consistent with the NTP’s standard protocol, all dose groups were compared with the untreated vehicle control group, and we did not perform multiple testing adjustments for different tumor types. We did not use historical control data since there is no convenient historical database that would match data with each study used in this investigation.</p>
</sec>
</sec>
<sec id="section5-0192623312446527">
<title>Results</title>
<p>To identify gender differences in chemical carcinogenesis, 2-year rat NTP bioassay data were analyzed. This was done using the evidence level as an indicator of carcinogenic potential for the chemicals. A subset of 477 bioassays included both genders. Among these, 278 showed clear, some, or equivocal evidence for carcinogenicity and were identified as carcinogens. Of these 278 carcinogens, 13 exhibited tumors only in mammary or reproductive organs and were excluded from further analysis. Two hundred and one exhibited some type of gender difference in nonreproductive organs, as defined in the Methods section (<xref ref-type="table" rid="table1-0192623312446527">Table 1</xref>). Eighty-seven (31%) gave tumors in either males or females (68 in males only and 19 in females only). One hundred and two gave tumors in at least one organ in one sex but showed no evidence in the same organ in the other sex (62 in males and 40 in females). A third category was 12 chemicals that gave tumors in both sexes but significantly more in one sex (8 in males and 4 in females; <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref>). Thus, of 278 agents, 87 were gender specific, and the rest, 191 agents, induced tumors in both sexes. It is also apparent from <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref> that there was a male dominance with, for example, 68 assays with tumors in males only and 19 in females only. In further analysis, we excluded equivocal test results and found even stronger dominance for males. Thus, 40 male-specific and 7 female-specific chemicals were identified. In other words, male-specific chemicals were 5.7 times more common than female-specific chemicals when these more stringent criteria for carcinogenic activity (see the Methods section) were used. All these data indicate that male rats were more susceptible to chemical carcinogenesis in nonreproductive organs.</p>
<table-wrap id="table1-0192623312446527" position="float">
<label>Table 1.</label>
<caption>
<p>Gender differences in National Toxicology Program rat cancer bioassays.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0192623312446527" xlink:href="10.1177_0192623312446527-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="3">Number of gender-specific carcinogens</th>
</tr>
<tr>
<th>
</th>
<th>Male</th>
<th>Female</th>
<th>
</th>
</tr>
<tr>
<th>Gender difference categories</th>
<th>Clear, some, equivocal evidence<sup>b</sup>
</th>
<th>Clear, some, equivocal evidence<sup>b</sup>
</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumors in one sex only</td>
<td>68*</td>
<td>19</td>
<td>87</td>
</tr>
<tr>
<td>Tumors in both sexes, but organ-specific tumors in one sex<sup>c</sup>
</td>
<td>62*</td>
<td>40</td>
<td>102</td>
</tr>
<tr>
<td>Tumors in the same organ in males and females, but with significant difference<sup>c</sup>
</td>
<td>8</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td>
</td>
<td align="center">Clear, some evidence<sup>d</sup>
</td>
<td align="center">Clear, some evidence<sup>d</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>Tumors in one sex only</td>
<td>40*</td>
<td>7</td>
<td>47</td>
</tr>
<tr>
<td>Tumors in both sexes, but organ-specific tumors in one sex<sup>b</sup>
</td>
<td>53*</td>
<td>26</td>
<td>79</td>
</tr>
<tr>
<td>Tumors in the same organ in males and females, but with significant difference<sup>b</sup>
</td>
<td>8</td>
<td>4</td>
<td>12</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0192623312446527">
<p>
<sup>a </sup>Four hundred and seventy-seven rat bioassays were analyzed (http://ntp.niehs.nih.gov/).</p>
</fn>
<fn id="table-fn2-0192623312446527">
<p>
<sup>b </sup>Gender differences based on clear, some, and equivocal evidence.</p>
</fn>
<fn id="table-fn3-0192623312446527">
<p>
<sup>c </sup>Five carcinogens were included in both of these categories.</p>
</fn>
<fn id="table-fn4-0192623312446527">
<p>
<sup>d </sup>Gender differences were based on clear and some evidence.</p>
</fn>
<fn id="table-fn5-0192623312446527">
<p>* Significantly greater than the opposite gender, <italic>p</italic> ≤ .05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We also performed an overall analysis of data including all nonreproductive and reproductive organs. It revealed that male rats were 1.69 times (<italic>p </italic>&lt; .001) more often classified to a higher level of evidence for carcinogenic activity than female rats.</p>
<p>Most bioassays (86%) employed Fischer 344 rats (<xref ref-type="bibr" rid="bibr21-0192623312446527">King-Herbert, Sills, and Bucher 2010</xref>), and we did not observe any bias for other strains among bioassays showing gender differences. There was a change in diet 1995, which has been reported to affect tumor incidences of, for example, pituitary and testis tumors (<xref ref-type="bibr" rid="bibr16-0192623312446527">Haseman et al. 2003</xref>). However, most bioassays used in these studies were performed prior to the food change, and we did not observe trend changes in later studies. The publication years for bioassays used in this study are given in supplementary <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref>. As can be seen, assays exhibiting gender dimorphisms were evenly spread over the years, and we did not observe trends that can be explained by, for example, genetic drift among test animals. Likewise, we did not observe any bias for route of exposure.</p>
<p>
<xref ref-type="table" rid="table2-0192623312446527">Table 2</xref> shows the fraction of rat carcinogens inducing tumors in an organ or tissue in a gender-specific way (i.e., there were tumors in one organ/site in one sex but no tumors in the same organ/site in the other sex). <xref ref-type="table" rid="table2-0192623312446527">Table 2</xref> is based on results from 189 (87 + 102) bioassays (or carcinogens) shown in <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref> and lists 171 positive male organs and tissue sites and 70 positive female sites. It should be noted that some chemicals were multisite carcinogens. The results are presented as fractions and percentages of the total number of chemicals inducing tumors at the same site. Overall, males were more affected, and more often tumors were induced in male rats than in female rats. The four sites that exhibited the highest fractions of male-specific tumors were mesothelium (mesotheliomas; 83% of all mesothelioma-inducing carcinogens), pancreas (79%), kidney (64%), and skin (58%). The four sites that exhibited the highest fractions of female-specific tumors were pituitary (80%), bone marrow and lymphoid tissues (leukemias and lymphomas; 47%), lung (33%), and urinary bladder (29%). Fifteen of 18 chemicals inducing mesotheliomas induced this tumor in males only. Of importance is that the majority, if not all, of mesotheliomas likely derived from the male-specific <italic>tunica vaginals</italic> in scrotum (<xref ref-type="bibr" rid="bibr14-0192623312446527">Haber et al. 2009</xref>) and may thus be regarded as a male-specific reproductive organ tumor.</p>
<table-wrap id="table2-0192623312446527" position="float">
<label>Table 2.</label>
<caption>
<p>Target organs/tissue for gender-specific carcinogenic responses in National Toxicology Program rat bioassays.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0192623312446527" xlink:href="10.1177_0192623312446527-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="8">Fraction and percentage of gender-specific carcinogens</th>
</tr>
<tr>
<th>
</th>
<th align="center" colspan="4">Clear, some, equivocal<sup>b</sup>
</th>
<th align="center" colspan="4">Clear, some<sup>c</sup>
</th>
</tr>
<tr>
<th>Target organ/tissue</th>
<th align="center" colspan="2">Male<sup>d</sup>
</th>
<th align="center" colspan="2">Female<sup>d</sup>
</th>
<th align="center" colspan="2">Male<sup>d</sup>
</th>
<th align="center" colspan="2">Female<sup>d</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver<sup>e</sup>
</td>
<td>16/63</td>
<td>25%</td>
<td>8/63</td>
<td>13%</td>
<td>11/55</td>
<td>20%</td>
<td>6/55</td>
<td>11%</td>
</tr>
<tr>
<td>Thyroid</td>
<td>9/32</td>
<td>28%</td>
<td>5/32</td>
<td>16%</td>
<td>5/23</td>
<td>22%</td>
<td>3/23</td>
<td>13%</td>
</tr>
<tr>
<td>Kidney</td>
<td>42/66</td>
<td>64%*</td>
<td>5/66</td>
<td>8%</td>
<td>35/57</td>
<td>61%*</td>
<td>3/57</td>
<td>5%</td>
</tr>
<tr>
<td>Intestine</td>
<td>5/16</td>
<td>31%*</td>
<td>1/16</td>
<td>6%</td>
<td>4/14</td>
<td>29%</td>
<td>1/14</td>
<td>7%</td>
</tr>
<tr>
<td>Forestomach</td>
<td>3/21</td>
<td>14%</td>
<td>0/21</td>
<td>0%</td>
<td>3/20</td>
<td>15%*</td>
<td>0/20</td>
<td>0%</td>
</tr>
<tr>
<td>Leukemia, lymphoma</td>
<td>10/32</td>
<td>31%</td>
<td>15/32</td>
<td>47%</td>
<td>9/23</td>
<td>39%</td>
<td>8/23</td>
<td>35%</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>12/31</td>
<td>39%</td>
<td>8/31</td>
<td>26%</td>
<td>7/20</td>
<td>35%</td>
<td>4/20</td>
<td>20%</td>
</tr>
<tr>
<td>Lung</td>
<td>6/24</td>
<td>25%</td>
<td>8/24</td>
<td>33%</td>
<td>4/21</td>
<td>19%</td>
<td>7/21</td>
<td>33%</td>
</tr>
<tr>
<td>Vascular system</td>
<td>5/10</td>
<td>50%*</td>
<td>2/10</td>
<td>20%</td>
<td>4/8</td>
<td>50%*</td>
<td>1/8</td>
<td>13%</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>4/21</td>
<td>19%</td>
<td>6/21</td>
<td>29%</td>
<td>4/18</td>
<td>22%</td>
<td>2/18</td>
<td>17%</td>
</tr>
<tr>
<td>Mesothelium</td>
<td>15/18</td>
<td>83%*</td>
<td>0/18</td>
<td>0%</td>
<td>13/15</td>
<td>87%*</td>
<td>0/15</td>
<td>0%</td>
</tr>
<tr>
<td>Brain</td>
<td>3/8</td>
<td>38%</td>
<td>2/8</td>
<td>25%</td>
<td>0/2</td>
<td>0%</td>
<td>0/2</td>
<td>0%</td>
</tr>
<tr>
<td>Nasal cavity</td>
<td>4/15</td>
<td>27%*</td>
<td>0/15</td>
<td>0%</td>
<td>3/13</td>
<td>23%*</td>
<td>0/13</td>
<td>0%</td>
</tr>
<tr>
<td>Spleen<sup>f</sup>
</td>
<td>4/8</td>
<td>50%</td>
<td>1/8</td>
<td>13%</td>
<td>3/7</td>
<td>43%</td>
<td>1/7</td>
<td>14%</td>
</tr>
<tr>
<td>Pancreas</td>
<td>11/14</td>
<td>79%*</td>
<td>0/14</td>
<td>0%</td>
<td>6/9</td>
<td>67%*</td>
<td>0/9</td>
<td>0%</td>
</tr>
<tr>
<td>Pituitary</td>
<td>1/5</td>
<td>20%</td>
<td>4/5</td>
<td>80%*</td>
<td>0/1</td>
<td>0%</td>
<td>0/1</td>
<td>0%</td>
</tr>
<tr>
<td>Skin</td>
<td>14/24</td>
<td>58%*</td>
<td>2/24</td>
<td>8%</td>
<td>10/20</td>
<td>50%*</td>
<td>2/20</td>
<td>10%</td>
</tr>
<tr>
<td>Subcutaneous tissue</td>
<td>4/8</td>
<td>50%*</td>
<td>1/8</td>
<td>13%</td>
<td>4/7</td>
<td>57%*</td>
<td>0/7</td>
<td>0%</td>
</tr>
<tr>
<td>Oral cavity<sup>g</sup>
</td>
<td>2/15</td>
<td>13%</td>
<td>2/15</td>
<td>13%</td>
<td>2/15</td>
<td>13%</td>
<td>2/15</td>
<td>13%</td>
</tr>
<tr>
<td>Ureter</td>
<td>1/2</td>
<td>50%</td>
<td>0/2</td>
<td>0%</td>
<td>1/2</td>
<td>50%</td>
<td>0/2</td>
<td>0%</td>
</tr>
<tr>
<td>Weighted average</td>
<td>
</td>
<td>39%</td>
<td>
</td>
<td>16%</td>
<td>
</td>
<td>37%</td>
<td>
</td>
<td>12%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0192623312446527">
<p>
<sup>a </sup>Four hundred and seventy-seven rat bioassays were analyzed in the National Toxicology Program database (http://ntp.niehs.nih.gov/).</p>
</fn>
<fn id="table-fn7-0192623312446527">
<p>
<sup>b </sup>Gender differences based on clear, some, and equivocal evidence.</p>
</fn>
<fn id="table-fn8-0192623312446527">
<p>
<sup>c </sup>Gender differences based on clear and some evidence.</p>
</fn>
<fn id="table-fn9-0192623312446527">
<p>
<sup>d </sup>The first column gives the fraction of gender-specific chemicals per total number of chemicals inducing tumors at the respective target site; the second column gives the percentage of gender-specific chemicals.</p>
</fn>
<fn id="table-fn10-0192623312446527">
<p>
<sup>e </sup>Mainly hepatocellular tumors.</p>
</fn>
<fn id="table-fn11-0192623312446527">
<p>
<sup>f </sup>Designated as sarcomas.</p>
</fn>
<fn id="table-fn12-0192623312446527">
<p>
<sup>g </sup>Epithelial tumors.</p>
</fn>
<fn id="table-fn13-0192623312446527">
<p>* Significantly greater than the opposite gender, <italic>p</italic> ≤ .05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Another conspicuous finding was that 11 chemicals of 14 pancreatic carcinogens induced tumors in males only and none in females. Eight chemicals induced exocrine pancreatic cancer in males only but none in females only. In other organs, such as lung, both female- and male-specific carcinogens were identified. Female-specific carcinogens dominated among chemicals inducing leukemia and lymphoma. Interestingly, for some organ/tissues, a high proportion of carcinogens gave gender-specific responses. For example, 78% (31% in males and 47% in females) of chemicals induced leukemia/lymphoma in one gender only. Also for lung carcinogens, the majority (58%) induced tumors in one gender only (25% and 33%, respectively). All gender-specific carcinogens (and their technical report numbers) are listed in supplementary <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref>. As expected, male-specific carcinogens causing tumors in the kidney were common (64%), whereas female-specific carcinogens causing tumors in the kidney were uncommon (8%). When results assigned equivocal evidence were excluded, a male dominance was even stronger. However, the isolated female dominance regarding pituitary tumors was lost. The difference in weighted averages was strengthened (<xref ref-type="table" rid="table2-0192623312446527">Table 2</xref>).</p>
<p>Weighted averages for all listed organs affected by gender-specific carcinogens were 39% for males and 16% for females (<xref ref-type="table" rid="table2-0192623312446527">Table 2</xref>). If mesotheliomas were excluded, the weighted averages were 38% for males and 18% for females. Many kidney tumors and splenic leukemia have previously been discussed as rat specific, and if these two tumor types were excluded, the weighted averages were 35% for males and 18% for females. If all these three tumors types (mesothelioma, kidney, and splenic leukemia) were excluded, the weighted averages were 32% for males and 19% for females. If chemicals with equivocal evidence were excluded as well, weighted averages were 28% for males and 14% for females.</p>
<p>
<xref ref-type="table" rid="table3-0192623312446527">Table 3</xref> shows the number of chemicals in the NTP database inducing tumors in both genders but statistically significantly more in one gender. <xref ref-type="table" rid="table3-0192623312446527">Table 3</xref> is based on results from 12 bioassays, but 5 of these were also included in <xref ref-type="table" rid="table2-0192623312446527">Table 2</xref> as they also exhibited gender-specific tumor sites. Only three organs were affected in this way, and again males were more affected. The list of individual chemicals and technical report numbers are shown in supplementary <xref ref-type="table" rid="table2-0192623312446527">Table 2</xref>.</p>
<table-wrap id="table3-0192623312446527" position="float">
<label>Table 3.</label>
<caption>
<p>Number of chemicals in National Toxicology Program rat bioassays<sup>a</sup> inducing tumors in both genders but statistically significantly more in one gender.<sup>b</sup>
</p>
</caption>
<graphic alternate-form-of="table3-0192623312446527" xlink:href="10.1177_0192623312446527-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="4">Fraction and percentage<sup>c </sup>of gender-specific carcinogens</th>
</tr>
<tr>
<th>Target organ/tissue</th>
<th colspan="2">Male</th>
<th colspan="2">Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>4/63</td>
<td>6%</td>
<td>3/63</td>
<td>5%</td>
</tr>
<tr>
<td>Lung</td>
<td>3/24</td>
<td>13%</td>
<td>1/24</td>
<td>4%</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>1/31</td>
<td>3%</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn14-0192623312446527">
<p>
<sup>a </sup>Statistically significant difference between genders in respective organ.</p>
</fn>
<fn id="table-fn15-0192623312446527">
<p>
<sup>b </sup>Four hundred and seventy-seven rat bioassays were analyzed (http://ntp.niehs.nih.gov/).</p>
</fn>
<fn id="table-fn16-0192623312446527">
<p>
<sup>c </sup>The first column gives the fraction of chemicals giving more tumors in respective gender/total number of chemicals inducing tumors at the same site. The second column gives the percentage</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Next, we studied how often the 189 gender-specific carcinogens, analyzed in <xref ref-type="table" rid="table2-0192623312446527">Table 2</xref>, induced tumors at other sites in the same gender. <xref ref-type="table" rid="table4-0192623312446527">Table 4</xref> shows that weighted average for both male-specific and female-specific carcinogens inducing additional tumors in the same gender was high, 55% and 59%, respectively. We also analyzed whether the gender-specific carcinogens induced tumors in other nonreproductive organs in the opposite gender. As shown in <xref ref-type="table" rid="table5-0192623312446527">Table 5</xref>, both gender/organ-specific carcinogens in males and females commonly induced tumors in other organs in the opposite gender. For skin-inducing carcinogens, 11 of 14 induced additional tumors in females. The weighted average of male organ–specific carcinogens inducing other tumors in females was 46%, and the weighted average of female organ–specific carcinogens inducing other tumors in males was 66% (<xref ref-type="table" rid="table5-0192623312446527">Table 5</xref>).</p>
<table-wrap id="table4-0192623312446527" position="float">
<label>Table 4.</label>
<caption>
<p>Gender-specific rat carcinogens inducing tumors in other organs in the same gender.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table4-0192623312446527" xlink:href="10.1177_0192623312446527-table4.tif"/>
<table>
<thead>
<tr>
<th>Target organ/tissue</th>
<th colspan="2">Male-specific carcinogens inducing tumors in other organs in males<sup>b</sup>
</th>
<th colspan="2">Female-specific carcinogens inducing tumors in other organs in females<sup>b</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>9/16</td>
<td>(56%)</td>
<td>6/8</td>
<td>(75%)</td>
</tr>
<tr>
<td>Thyroid</td>
<td>4/9</td>
<td>(44%)</td>
<td>2/5</td>
<td>(40%)</td>
</tr>
<tr>
<td>Kidney</td>
<td>17/42</td>
<td>(40%)</td>
<td>2/5</td>
<td>(40%)</td>
</tr>
<tr>
<td>Intestine</td>
<td>3/5</td>
<td>(60%)</td>
<td>1/1</td>
<td>(100%)</td>
</tr>
<tr>
<td>Forestomach</td>
<td>2/3</td>
<td>(67%)</td>
<td>0/0</td>
<td>
</td>
</tr>
<tr>
<td>Leukemia, lymphoma</td>
<td>7/10</td>
<td>(70%)</td>
<td>7/15</td>
<td>(47%)</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>4/12</td>
<td>(30%)</td>
<td>6/8</td>
<td>(75%)</td>
</tr>
<tr>
<td>Lung</td>
<td>5/6</td>
<td>(83%)</td>
<td>7/8</td>
<td>(87%)</td>
</tr>
<tr>
<td>Vascular system</td>
<td>3/5</td>
<td>(60%)</td>
<td>1/2</td>
<td>(50%)</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>2/4</td>
<td>(50%)</td>
<td>4/6</td>
<td>(67%)</td>
</tr>
<tr>
<td>Mesothelium</td>
<td>12/15</td>
<td>(67%)</td>
<td>0/0</td>
<td>
</td>
</tr>
<tr>
<td>Brain</td>
<td>3/3</td>
<td>(100%)</td>
<td>1/2</td>
<td>(50%)</td>
</tr>
<tr>
<td>Nasal cavity</td>
<td>2/4</td>
<td>(50%)</td>
<td>0/0</td>
<td>
</td>
</tr>
<tr>
<td>Spleen</td>
<td>1/4</td>
<td>(25%)</td>
<td>0/1</td>
<td>(0%)</td>
</tr>
<tr>
<td>Pancreas</td>
<td>7/11</td>
<td>(64%)</td>
<td>0/0</td>
<td>
</td>
</tr>
<tr>
<td>Pituitary</td>
<td>0/1</td>
<td>(0%)</td>
<td>1/4</td>
<td>(25%)</td>
</tr>
<tr>
<td>Skin</td>
<td>9/14</td>
<td>(64%)</td>
<td>1/2</td>
<td>(50%)</td>
</tr>
<tr>
<td>Subcutaneous tissue</td>
<td>3/4</td>
<td>(75%)</td>
<td>0/1</td>
<td>
</td>
</tr>
<tr>
<td>Oral cavity</td>
<td>1/2</td>
<td>(50%)</td>
<td>2/2</td>
<td>(100%)</td>
</tr>
<tr>
<td>Ureter</td>
<td>1/1</td>
<td>(100%)</td>
<td>0/0</td>
<td>
</td>
</tr>
<tr>
<td>Weighted average</td>
<td>
</td>
<td>55%</td>
<td>
</td>
<td>59%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn17-0192623312446527">
<p>
<sup>a </sup>Gender-specific target site responses (http://ntp.niehs.nih.gov/) were analyzed for additional targets in the same gender (and the same bioassay).</p>
</fn>
<fn id="table-fn18-0192623312446527">
<p>
<sup>b </sup>The first column gives the fraction of gender-specific carcinogens (see <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref>) inducing tumors at additional sites in the same gender per total number of gender-specific targets (%). The second column gives the percentage of carcinogens inducing tumors at additional sites.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0192623312446527" position="float">
<label>Table 5.</label>
<caption>
<p>Gender-specific rat carcinogens inducing tumors in other organs in the other gender.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table5-0192623312446527" xlink:href="10.1177_0192623312446527-table5.tif"/>
<table>
<thead>
<tr>
<th>Target organ/tissue</th>
<th colspan="2">Male-specific carcinogens inducing tumors in females<sup>b</sup>
</th>
<th colspan="2">Female-specific carcinogens inducing tumors in males<sup>b</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>7/16</td>
<td>44%</td>
<td>7/8</td>
<td>88%</td>
</tr>
<tr>
<td>Thyroid</td>
<td>2/9</td>
<td>22%</td>
<td>2/5</td>
<td>40%</td>
</tr>
<tr>
<td>Kidney</td>
<td>14/42</td>
<td>33%</td>
<td>1/5</td>
<td>20%</td>
</tr>
<tr>
<td>Intestine</td>
<td>3/5</td>
<td>60%</td>
<td>1/1</td>
<td>100%</td>
</tr>
<tr>
<td>Forestomach</td>
<td>1/3</td>
<td>33%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Leukemia, lymphoma</td>
<td>4/10</td>
<td>40%</td>
<td>9/15</td>
<td>60%</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>4/12</td>
<td>33%</td>
<td>5/8</td>
<td>63%</td>
</tr>
<tr>
<td>Lung</td>
<td>5/6</td>
<td>83%</td>
<td>6/8</td>
<td>75%</td>
</tr>
<tr>
<td>Vascular system</td>
<td>4/5</td>
<td>80%</td>
<td>1/2</td>
<td>50%</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>2/4</td>
<td>50%</td>
<td>4/6</td>
<td>67%</td>
</tr>
<tr>
<td>Mesothelium</td>
<td>11/15</td>
<td>73%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Brain</td>
<td>1/3</td>
<td>33%</td>
<td>2/2</td>
<td>100%</td>
</tr>
<tr>
<td>Nasal cavity</td>
<td>0/4</td>
<td>0%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Spleen</td>
<td>1/4</td>
<td>25%</td>
<td>1/1</td>
<td>100%</td>
</tr>
<tr>
<td>Pancreas</td>
<td>3/11</td>
<td>27%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Pituitary</td>
<td>0/1</td>
<td>0%</td>
<td>3/4</td>
<td>75%</td>
</tr>
<tr>
<td>Skin</td>
<td>11/14</td>
<td>79%</td>
<td>1/2</td>
<td>50%</td>
</tr>
<tr>
<td>Subcutaneous tissue</td>
<td>3/4</td>
<td>75%</td>
<td>1/1</td>
<td>100%</td>
</tr>
<tr>
<td>Oral cavity</td>
<td>1/2</td>
<td>50%</td>
<td>2/2</td>
<td>100%</td>
</tr>
<tr>
<td>Ureter</td>
<td>1/1</td>
<td>100%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Weighted average</td>
<td>
</td>
<td>46%</td>
<td>
</td>
<td>66%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn19-0192623312446527">
<p>
<sup>a </sup>Gender-specific target site responses (http://ntp.niehs.nih.gov/) were analyzed for additional targets in the same gender and the same bioassay.</p>
</fn>
<fn id="table-fn20-0192623312446527">
<p>
<sup>b </sup>The first column is the fraction of gender-specific carcinogens (see <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref>) inducing tumors at additional sites in the other gender per total number of gender-specific targets. The second column gives the percentage of carcinogens inducing tumors at additional sites.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Male- and female-specific carcinogens may have different modes of action (MOA), and we investigated whether gender-specific chemicals (analyzed in <xref ref-type="table" rid="table2-0192623312446527">Tables 2</xref>, <xref ref-type="table" rid="table4-0192623312446527">4</xref>, and <xref ref-type="table" rid="table5-0192623312446527">5</xref>) could be classified as genotoxic or nongenotoxic. For this classification, we used test results given by NTP and classified chemicals as genotoxic if the Salmonella assay was positive in at least one test (for more comprehensive results, see supplementary <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref>). Weakly positive results according to NTP were classified as negative. Overall, genotoxicity was indicated for 38% (105) of 278 carcinogenic chemicals in the NTP database. <xref ref-type="table" rid="table6-0192623312446527">Table 6</xref> shows the fraction of gender-specific carcinogens that were classified as genotoxic. The weighted average for male-specific carcinogens was 43%, and for female-specific carcinogens, the same value was 31%. These data indicate an overall difference in genotoxicity between male- and female-specific carcinogens. Ten (71%) male-specific skin carcinogens were genotoxic, and five (45%) of pancreatic carcinogens were genotoxic. Also among leukemia- and lymphoma-inducing male-specific carcinogens, genotoxic chemicals dominated. Thus, 60% of male-specific chemicals were genotoxic, while the corresponding value for female-specific carcinogens was 13%. However, the male dominance among genotoxic chemicals was not true for all tumor sites. For example, 63% (5/8) of female-specific lung carcinogens were genotoxic, while 33% (2/6) of male-specific lung carcinogens were genotoxic (<xref ref-type="table" rid="table6-0192623312446527">Table 6</xref>). Together, these data indicate differences in genotoxicity between male- and female-specific carcinogens and that genotoxicity was more common among male- than among female-specific carcinogens. An exception was lung carcinogens.</p>
<table-wrap id="table6-0192623312446527" position="float">
<label>Table 6.</label>
<caption>
<p>Genotoxicity<sup>a</sup> among rat carcinogens inducing gender-specific tumors.<sup>b</sup>
</p>
</caption>
<graphic alternate-form-of="table6-0192623312446527" xlink:href="10.1177_0192623312446527-table6.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th colspan="4">Fraction and percentage of genotoxic and gender-specific carcinogens<sup>c</sup>
</th>
</tr>
<tr>
<th>Target organ/tissue</th>
<th align="center" colspan="2">Male</th>
<th align="center" colspan="2">Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>8/16</td>
<td>50%</td>
<td>3/8</td>
<td>38%</td>
</tr>
<tr>
<td>Thyroid</td>
<td>4/9</td>
<td>44%</td>
<td>2/5</td>
<td>40%</td>
</tr>
<tr>
<td>Kidney</td>
<td>8/42</td>
<td>19%</td>
<td>1/5</td>
<td>20%</td>
</tr>
<tr>
<td>Intestine</td>
<td>3/5</td>
<td>60%</td>
<td>1/1</td>
<td>100%</td>
</tr>
<tr>
<td>Forestomach</td>
<td>3/3</td>
<td>100%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Leukemia, lymphoma</td>
<td>6/10</td>
<td>60%</td>
<td>2/15</td>
<td>13%</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>3/12</td>
<td>25%</td>
<td>1/8</td>
<td>13%</td>
</tr>
<tr>
<td>Lung</td>
<td>2/6</td>
<td>33%</td>
<td>5/8</td>
<td>63%</td>
</tr>
<tr>
<td>Vascular system</td>
<td>4/5</td>
<td>80%</td>
<td>0/2</td>
<td>0%</td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>1/4</td>
<td>25%</td>
<td>2/6</td>
<td>33%</td>
</tr>
<tr>
<td>Mesothelium</td>
<td>8/15</td>
<td>53%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Brain</td>
<td>0/3</td>
<td>0%</td>
<td>2/2</td>
<td>100%</td>
</tr>
<tr>
<td>Nasal cavity</td>
<td>2/4</td>
<td>50%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Spleen</td>
<td>1/4</td>
<td>25%</td>
<td>0/1</td>
<td>0%</td>
</tr>
<tr>
<td>Pancreas</td>
<td>5/11</td>
<td>45%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Pituitary</td>
<td>1/1</td>
<td>100%</td>
<td>0/4</td>
<td>0%</td>
</tr>
<tr>
<td>Skin</td>
<td>10/14</td>
<td>71%</td>
<td>1/2</td>
<td>50%</td>
</tr>
<tr>
<td>Subcutaneous tissue</td>
<td>4/4</td>
<td>100%</td>
<td>0/1</td>
<td>0%</td>
</tr>
<tr>
<td>Oral cavity</td>
<td>0/2</td>
<td>0%</td>
<td>2/2</td>
<td>100%</td>
</tr>
<tr>
<td>Ureter</td>
<td>0/1</td>
<td>0%</td>
<td>0/0</td>
<td align="center">—</td>
</tr>
<tr>
<td>Weighted average</td>
<td>
</td>
<td>43%</td>
<td>
</td>
<td>31%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn21-0192623312446527">
<p>
<sup>a </sup>All positive results except “weakly positive” results given by the National Toxicology Program (http://ntp.niehs.nih.gov/) generated a positive classification.</p>
</fn>
<fn id="table-fn22-0192623312446527">
<p>
<sup>b </sup>Carcinogens inducing gender-specific carcinogenic responses were analyzed.</p>
</fn>
<fn id="table-fn23-0192623312446527">
<p>
<sup>c </sup>Number and fraction of gender-specific responses induced by genotoxic chemicals/total number of responses with gender-specific tumors (see <xref ref-type="table" rid="table1-0192623312446527">Table 1</xref>).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-0192623312446527">
<title>Discussion</title>
<p>There are numerous publications showing gender differences in carcinogenicity, but the contribution of sex-specific susceptibility for carcinogens is to a large extent unknown. We found that of 278 rat carcinogens in the NTP database, 201 exhibit gender differences in at least one tumor site. Sixty-eight of these chemicals induced tumors only in males, and 19 induced tumor in females only. The male sensitivity is further supported by the fact that male rats were 1.69 (<italic>p </italic>&lt; .001) times more often classified to a higher level of evidence for carcinogenicity than female rats. We thus conclude that gender-specific responses to carcinogens are common and that males are more often affected. In the site-specific analysis, we found that mesothelium, pancreas, kidney, and skin exhibited the highest frequencies of male-specific tumors. The male dominance is quite strong, and to our knowledge, this observation has not previously been discussed.</p>
<p>We do not have an overarching explanation for the male dominance. However, there are two recent human studies showing a similar pattern. These studies, comparing incidence rates for men and women, concluded that there might be “universal mechanisms that increase male susceptibility to cancer” (<xref ref-type="bibr" rid="bibr8-0192623312446527">Cook et al. 2009</xref>) or might be “intrinsic sex specific biological factors . . . modify the susceptibility to extrinsic oncogenic factors” (<xref ref-type="bibr" rid="bibr9-0192623312446527">Edgren et al. 2012</xref>). Our data tend to support these conclusions, although human incidence rates are affected by infections, food habits, obesity, and other factors presumably not influencing NTP assays. It is interesting to note that <xref ref-type="bibr" rid="bibr8-0192623312446527">Cook et al. (2009</xref>) found that the overall male-to-female incidence rate ratio (IRR) was 1.77 for cancers in nonsex organs. This IRR is not directly comparable but strikingly similar to our overall male-to-female ratio of 1.69, which is based on NTP evidence levels. Future studies may clarify if this similarity is coincident or if it reflects a common biology in human and rat.</p>
<p>The intention with our study was to perform a statistical analysis of the NTP database to document gender differences in response to chemical carcinogens and to get support for future mechanistic studies. Such future studies may also include a more detailed analysis of different tumor types at a single site. Here we will discuss our site-specific findings in connection to already published data.</p>
<p>Male-specific mesotheliomas originating in the tunica vaginalis might be regarded as a reproductive organ–derived tumor and will not be comprehensively discussed here. However, it is of interest that mesotheliomas in pleura or peritoneum in humans are far more common among men than among women (<xref ref-type="bibr" rid="bibr50-0192623312446527">Wolf et al. 2010</xref>), and it has been suggested that estrogen receptor (ER) β expression may confer resistance among women (<xref ref-type="bibr" rid="bibr42-0192623312446527">Pinton et al. 2010</xref>).</p>
<p>Male rats express a small protein, α2u-globulin, in liver and plasma, and its expression is androgen dependent (<xref ref-type="bibr" rid="bibr7-0192623312446527">Chatterjee et al. 1989</xref>). It is excreted in primary urine and is absorbed in kidney tubular cells. Xenobiotics, including many NTP test chemicals, may bind α2u-globulin and inhibit its degradation so that it accumulates in tubular cells and becomes toxic. The cytotoxicity may promote renal tubular tumor development (<xref ref-type="bibr" rid="bibr15-0192623312446527">Hard, Johnson, and Cohen 2009</xref>; <xref ref-type="bibr" rid="bibr28-0192623312446527">Leavens and Borghoff 2009</xref>), which may work in concert with a chronic progressive nephropathy (CPN) in male rats (<xref ref-type="bibr" rid="bibr15-0192623312446527">Hard, Johnson, and Cohen 2009</xref>). Both of these modes of action have been discussed as nonrelevant for humans (<xref ref-type="bibr" rid="bibr15-0192623312446527">Hard, Johnson, and Cohen 2009</xref>). Challenging is, however, that kidney cancer is more common among men (<xref ref-type="bibr" rid="bibr8-0192623312446527">Cook et al. 2009</xref>; <xref ref-type="bibr" rid="bibr24-0192623312446527">Knox and Colli 2011</xref>; <xref ref-type="bibr" rid="bibr9-0192623312446527">Edgren et al. 2012</xref>), and a significant proportion of renal cell carcinomas in humans express androgen receptor (AR; <xref ref-type="bibr" rid="bibr5-0192623312446527">Brown et al. 1998</xref>; <xref ref-type="bibr" rid="bibr26-0192623312446527">Langner et al. 2004</xref>). Further MOA analysis that can ascertain that rat male kidney carcinogens do not cause cancer via other mechanisms than α2u-globulin toxicity or CPN is thus warranted.</p>
<p>The male dominance regarding exocrine pancreatic cancer was discussed 20 years ago (<xref ref-type="bibr" rid="bibr31-0192623312446527">Longnecker 1990</xref>; <xref ref-type="bibr" rid="bibr32-0192623312446527">Longnecker and Sumi 1990</xref>), and our data confirm and extend those earlier observations. Rats (and mice) develop an acinar type of exocrine tumor, whereas humans usually develop a ductal type, and this phenotypic difference has raised questions about the relevance for humans of pancreatic carcinogenesis in rodents (<xref ref-type="bibr" rid="bibr34-0192623312446527">Maronpot, Flake, and Huff 2004</xref>). However, pancreatic cells exhibit great plasticity (<xref ref-type="bibr" rid="bibr44-0192623312446527">Puri and Hebrok 2010</xref>), and uncertainty still remains regarding cells of origin for ductal cancer (<xref ref-type="bibr" rid="bibr25-0192623312446527">Kong et al. 2011</xref>). Early work shows that caerulin promotes cancer development in rats by inducing growth of azaserine-induced acinar cell nodules (<xref ref-type="bibr" rid="bibr29-0192623312446527">Lhoste and Longnecker 1987</xref>), whereas caerulin-induced chronic pancreatitis leads to ductal carcinoma in mice harboring mutated K-ras in acinar or centroacinar cells (<xref ref-type="bibr" rid="bibr13-0192623312446527">Guerra et al. 2007</xref>). These data suggest that long-term treatments resulting in pancreatitis may promote ductal cancer development provided key oncogenic mutations are expressed in progenitor cells. Xenobiotic-induced ductal carcinomas in rats have also been reported (<xref ref-type="bibr" rid="bibr45-0192623312446527">Rivera et al. 1997</xref>), and it can be suggested that the induction of acinar carcinomas in the NTP tests reflects critical carcinogenic stimuli that may result in either acinar or ductal carcinomas depending on whether cells of origin harbor, for example, K-ras mutations. Further studies are thus needed to understand the relevance, if any, of acinar rat pancreatic tumors for humans. It should also be noted that pancreatic cancer is more common among males (<xref ref-type="bibr" rid="bibr8-0192623312446527">Cook et al. 2009</xref>; <xref ref-type="bibr" rid="bibr9-0192623312446527">Edgren et al. 2012</xref>) and that young men (&lt;60 years of age) are 1.6 times more likely to develop this neoplasm than young women (<xref ref-type="bibr" rid="bibr55-0192623312446527">Zhou et al. 2010</xref>). This difference might be explained by, for example, differences in alcohol consumption, but AR signaling has been reported in pancreatic cancer (<xref ref-type="bibr" rid="bibr40-0192623312446527">Okitsu et al. 2010</xref>). Furthermore, there are epidemiological studies supporting a male-specific susceptibility to, for example, crystalline silica dust (<xref ref-type="bibr" rid="bibr4-0192623312446527">Birk et al. 2009</xref>) and to red meat (<xref ref-type="bibr" rid="bibr27-0192623312446527">Larsson and Wolk 2012</xref>).</p>
<p>We also evaluated data on genotoxicity in the NTP database. Genotoxicity was 1.4 times more common among the male-specific carcinogens than among the female-specific carcinogens. Considering, for example, the high numbers of nongenotoxic kidney carcinogens in male rats, this figure is surprisingly high. A site-specific analysis is hampered by low numbers in many cases, but it is interesting to note that 63% of female-specific lung carcinogens were genotoxic, whereas only 33% of male-specific lung carcinogens were genotoxic. This suggests a greater susceptibility among female rats for genotoxic lung carcinogens and is in line with epidemiology suggesting that women are more susceptible to tobacco smoking (<xref ref-type="bibr" rid="bibr23-0192623312446527">Kiyohara and Ohno 2010</xref>). Further support is provided by biomonitoring data on susceptibility to tobacco mutagens among women (<xref ref-type="bibr" rid="bibr22-0192623312446527">Kirsch-Volders et al. 2010</xref>) and by lung epithelial cell studies suggesting that xenobiotic metabolism in lung cells is tuned to give more DNA adducts in women (<xref ref-type="bibr" rid="bibr36-0192623312446527">Mollerup et al. 2006</xref>; <xref ref-type="bibr" rid="bibr49-0192623312446527">Uppstad et al. 2011</xref>). It has also been observed that expression of high levels of ERα receptors is associated with poor prognosis in men or women with lung cancer (<xref ref-type="bibr" rid="bibr41-0192623312446527">Olivo-Marston et al. 2010</xref>). This observation may reflect estrogen influences on lung carcinogenesis but may also reflect influences on cancer therapy.</p>
<p>Site-specific carcinogens in both males and females commonly induced tumors at other sites in both sexes. This suggests that the majority of site-specific effects were not a consequence of well-studied gender dimorphisms in xenobiotic metabolism (<xref ref-type="bibr" rid="bibr39-0192623312446527">Oertelt-Prigione and Regitz-Zagrosek 2009</xref>; <xref ref-type="bibr" rid="bibr22-0192623312446527">Kirsch-Volders et al. 2010</xref>), altering, for example, blood levels or elimination rates. A possible exception is urinary bladder tumors, which might be heavily influenced by excreted metabolites (<xref ref-type="bibr" rid="bibr54-0192623312446527">Zenser, Lakshmi, and Davis 1998</xref>). This tumor type did not exhibit marked differences between females and males in the NTP assays, so toxicokinetic differences may have concealed an influence of AR expression, as reported by <xref ref-type="bibr" rid="bibr35-0192623312446527">Miyamoto et al. (2007</xref>).</p>
<p>There is ample literature support for an influence of hormones in rats and humans. It may, for example, involve oncogenes and suppressor genes and their signaling pathways. Thus, hormonal- and age-related decline in p53 function, occurring later in male than in female mice, has been reported (<xref ref-type="bibr" rid="bibr10-0192623312446527">Feng et al. 2007</xref>). If this also occurs in rats, it may explain high incidences in 3-year-old female rats (<xref ref-type="bibr" rid="bibr3-0192623312446527">Anisimov, Ukraintseva, and Yashin 2005</xref>), and if it occurs in humans, it may explain the above-discussed susceptibility to tobacco smoke among women (<xref ref-type="bibr" rid="bibr22-0192623312446527">Kirsch-Volders et al. 2010</xref>). Other influences may include liver cancer–promoting effects of AR (<xref ref-type="bibr" rid="bibr52-0192623312446527">Yu et al. 2000</xref>; <xref ref-type="bibr" rid="bibr51-0192623312446527">Yoon et al. 2006</xref>; <xref ref-type="bibr" rid="bibr33-0192623312446527">Ma et al. 2008</xref>; <xref ref-type="bibr" rid="bibr53-0192623312446527">Zender and Kubicka 2008</xref>) or upstream regulators of AR (<xref ref-type="bibr" rid="bibr48-0192623312446527">Tsuei et al. 2011</xref>). Inhibiting effects of estrogen, decreasing IL-6 production, and inhibiting hepatocellular carcinoma development have also been shown (<xref ref-type="bibr" rid="bibr38-0192623312446527">Naugler et al. 2007</xref>). Of further interest is that shorter CAG repeats in the AR gene associate with hepatocellular carcinoma (<xref ref-type="bibr" rid="bibr52-0192623312446527">Yu et al. 2000</xref>) and with pulmonary, esophageal, or bladder cancer (<xref ref-type="bibr" rid="bibr47-0192623312446527">Teng et al. 2010</xref>) and that the expression of a transporter of hormones, including testosterone and estrogens, correlated to the differentiation of liver, colon, and other cancer types (<xref ref-type="bibr" rid="bibr43-0192623312446527">Pressler et al. 2011</xref>). Yet another example is that estrogen may have a protective effect in human stomach cancer (<xref ref-type="bibr" rid="bibr6-0192623312446527">Chandanos and Lagergren 2008</xref>). These studies support the notion that sex hormones may have influenced not only human cancers in nonreproductive organs but also our NTP data.</p>
<p>In summary, we show that gender-specific tumor responses in rats are common. We also show that male rats are more often affected than female rats by chemical carcinogens. The male dominance in rats is in line with human incidence rates being higher in males than in females. Thus, although some affected rat tumor sites are regarded as nonrelevant to humans, and, for example, male rat kidney tumors have been explained in molecular terms, the male dominance should be further studied with the aim to understand this susceptibility among male rats and men. Literature data on sex hormone receptor expression in nonreproductive organs might provide a base for one of several possible explanations. Further experimental and epidemiological studies may disclose interactions between chemical carcinogen and hormones overlooked in the past.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0192623312446527">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Swedish Research Council for the Environment, Agricultural Sciences and Spatial Planning (FORMAS) and by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences, project ES045005-14.</p>
</fn>
</fn-group>
<glossary content-type="abbr">
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="term1-0192623312446527">AR</term>
<def>
<p>androgen receptor</p>
</def>
</def-item>
<def-item>
<term id="term2-0192623312446527">ER</term>
<def>
<p>estrogen receptor</p>
</def>
</def-item>
<def-item>
<term id="term3-0192623312446527">MOA</term>
<def>
<p>mode of action</p>
</def>
</def-item>
<def-item>
<term id="term4-0192623312446527">NTP</term>
<def>
<p>National Toxicology Program</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="bibr1-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersen</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Clewell</surname>
<given-names>H. J.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Bermudez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Willson</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Formaldehyde: Integrating dosimetry, cytotoxicity, and genomics to understand dose-dependent transitions for an endogenous compound</article-title>. <source>Toxicol Sci</source> <volume>118</volume>, <fpage>716</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr2-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>G. D.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Sex and racial differences in pharmacological response: Where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics</article-title>. <source>J Womens Health (Larchmt)</source> <volume>14</volume>, <fpage>19</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr3-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anisimov</surname>
<given-names>V. N.</given-names>
</name>
<name>
<surname>Ukraintseva</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Yashin</surname>
<given-names>A. I.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Cancer in rodents: does it tell us about cancer in humans?</article-title> <source>Nat Rev Cancer</source> <volume>5</volume>, <fpage>807</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr4-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birk</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mundt</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Guldner</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Luippold</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Mortality in the German porcelain industry 1985-2005: First results of an epidemiological cohort study</article-title>. <source>J Occup Environ Med</source> <volume>51</volume>, <fpage>373</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr5-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Dababo</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Hladik</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Eagan</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>C. L.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Rushing</surname>
<given-names>E. J.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Hormone receptor immunoreactivity in hemangioblastomas and clear cell renal cell carcinomas</article-title>. <source>Mod Pathol</source> <volume>11</volume>, <fpage>55</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr6-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandanos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lagergren</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Oestrogen and the enigmatic male predominance of gastric cancer</article-title>. <source>Eur J Cancer</source> <volume>44</volume>, <fpage>2397</fpage>–<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr7-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chatterjee</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Demyan</surname>
<given-names>W. F.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Loss of androgenic induction of alpha 2u-globulin gene family in the liver of NIH black rats</article-title>. <source>Endocrinology</source> <volume>125</volume>, <fpage>1385</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr8-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cook</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Dawsey</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Freedman</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>Inskip</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Wichner</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Quraishi</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Devesa</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>McGlynn</surname>
<given-names>K. A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Sex disparities in cancer incidence by period and age</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>18</volume>, <fpage>1174</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr9-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edgren</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Adami</surname>
<given-names>H. O.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>E. T.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Enigmatic sex disparities in cancer incidence</article-title>. <source>Eur J Epidemiol</source> <volume>27</volume>, <fpage>187</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr10-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Teresky</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Hernando</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cordon-Cardo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>104</volume>, <fpage>16633</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr11-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folkerd</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Dowsett</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Influence of sex hormones on cancer progression</article-title>. <source>J Clin Oncol</source> <volume>28</volume>, <fpage>4038</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr12-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gochfeld</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Framework for gender differences in human and animal toxicology</article-title>. <source>Environ Res</source> <volume>104</volume>, <fpage>4</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr13-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerra</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schuhmacher</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Canamero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grippo</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Verdaguer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Perez-Gallego</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dubus</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sandgren</surname>
<given-names>E. P.</given-names>
</name>
<name>
<surname>Barbacid</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice</article-title>. <source>Cancer Cell</source> <volume>11</volume>, <fpage>291</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr14-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haber</surname>
<given-names>L. T.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kroner</surname>
<given-names>O. L.</given-names>
</name>
<name>
<surname>Kohrman</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Evaluation of human relevance and mode of action for tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide</article-title>. <source>Regul Toxicol Pharmacol</source> <volume>53</volume>, <fpage>134</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr15-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hard</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>A comparison of rat chronic progressive nephropathy with human renal disease-implications for human risk assessment</article-title>. <source>Crit Rev Toxicol</source> <volume>39</volume>, <fpage>332</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr16-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haseman</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Ney</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nyska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>G. N.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Effect of diet and animal care/housing protocols on body weight, survival, tumor incidences, and nephropathy severity of F344 rats in chronic studies</article-title>. <source>Toxicol Pathol</source> <volume>31</volume>, <fpage>674</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr17-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoenerhoff</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Ton</surname>
<given-names>T. V.</given-names>
</name>
<name>
<surname>Lahousse</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Sills</surname>
<given-names>R. C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>A review of the molecular mechanisms of chemically induced neoplasia in rat and mouse models in National Toxicology Program bioassays and their relevance to human cancer</article-title>. <source>Toxicol Pathol</source> <volume>37</volume>, <fpage>835</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr18-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huff</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Predicting chemicals causing cancer in animals as human carcinogens</article-title>. <source>Occup Environ Med</source> <volume>67</volume>, <fpage>720</fpage>.</citation>
</ref>
<ref id="bibr19-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>D. L.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The limits of two-year bioassay exposure regimens for identifying chemical carcinogens</article-title>. <source>Environ Health Perspect</source> <volume>116</volume>, <fpage>1439</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr20-0192623312446527">
<citation citation-type="other">
<collab collab-type="author">International Agency for Research on Cancer</collab>. (<year>2010</year>). <comment>Cancer Incidence in Five Continents, IARC Scientific Publications No. 155. International Agency for Research on Cancer, Lyon, France</comment>.</citation>
</ref>
<ref id="bibr21-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>King-Herbert</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Sills</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Bucher</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Commentary: Update on animal models for NTP studies</article-title>. <source>Toxicol Pathol</source> <volume>38</volume>, <fpage>180</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr22-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirsch-Volders</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bonassi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Herceg</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hirvonen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Moller</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>D. H.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Gender-related differences in response to mutagens and carcinogens</article-title>. <source>Mutagenesis</source> <volume>25</volume>, <fpage>213</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr23-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyohara</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Sex differences in lung cancer susceptibility: a review</article-title>. <source>Gend Med</source> <volume>7</volume>, <fpage>381</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr24-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knox</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Colli</surname>
<given-names>J. L.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Characterizing changes in kidney and renal pelvis cancer incidence from 1998 to 2006 in the United States</article-title>. <source>Int Urol Nephrol</source> <volume>43</volume>, <fpage>359</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr25-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Michalski</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Erkan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Friess</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kleeff</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>From tissue turnover to the cell of origin for pancreatic cancer</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> <volume>8</volume>, <fpage>467</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr26-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ratschek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rehak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schips</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zigeuner</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Steroid hormone receptor expression in renal cell carcinoma: An immunohistochemical analysis of 182 tumors</article-title>. <source>J Urol</source> <volume>171</volume>, <fpage>611</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr27-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsson</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Wolk</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Red and processed meat consumption and risk of pancreatic cancer: Meta-analysis of prospective studies</article-title>. <source>Br J Cancer</source> <volume>106</volume>, <fpage>603</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr28-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leavens</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Borghoff</surname>
<given-names>S. J.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Physiologically based pharmacokinetic model of methyl tertiary butyl ether and tertiary butyl alcohol dosimetry in male rats based on binding to alpha2u-globulin</article-title>. <source>Toxicol Sci</source> <volume>109</volume>, <fpage>321</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr29-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lhoste</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Longnecker</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>1987</year>). <article-title>Effect of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas</article-title>. <source>Cancer Res</source> <volume>47</volume>, <fpage>3273</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr30-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Giovannucci</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Sex hormones and colorectal cancer: What have we learned so far?</article-title> <source>J Natl Cancer Inst</source> <volume>102</volume>, <fpage>1746</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr31-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longnecker</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Experimental pancreatic cancer: role of species, sex and diet</article-title>. <source>Bull Cancer</source> <volume>77</volume>, <fpage>27</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr32-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longnecker</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Sumi</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Effects of sex steroid hormones on pancreatic cancer in the rat</article-title>. <source>Int J Pancreatol</source> <volume>7</volume>, <fpage>159</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr33-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Jou</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma</article-title>. <source>Gastroenterology</source> <volume>135</volume>, <fpage>947</fpage>–<lpage>55</lpage>, <volume>955</volume> <fpage>e941</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr34-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maronpot</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Flake</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Huff</surname>
<given-names>J</given-names>
</name>
</person-group>. (<year>2004</year>). <article-title>Relevance of animal carcinogenesis findings to human cancer predictions and prevention</article-title>. <source>Toxicol Pathol</source> <volume>32</volume> <issue>Suppl 1</issue>, <fpage>40</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr35-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Ishiguro</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Uemura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nagashima</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Messing</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Promotion of bladder cancer development and progression by androgen receptor signals</article-title>. <source>J Natl Cancer Inst</source> <volume>99</volume>, <fpage>558</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr36-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mollerup</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Berge</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Baera</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Skaug</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hewer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Stangeland</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Haugen</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts</article-title>. <source>Int J Cancer</source> <volume>119</volume>, <fpage>741</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr37-0192623312446527">
<citation citation-type="journal">
<collab collab-type="author">National Toxicology Program</collab>. (<year>2009</year>). <article-title>Toxicology and carcinogenesis studies of bromochloroacetic acid (CAS No. 5589-96-8) in F344/N rats and B6C3F1 mice (drinking water studies)</article-title>. <source>Natl Toxicol Program Tech Rep Ser</source> (<issue>540</issue>), <fpage>1</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr38-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naugler</surname>
<given-names>W. E.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Elsharkawy</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Karin</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production</article-title>. <source>Science</source> <volume>317</volume>, <fpage>121</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr39-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oertelt-Prigione</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Regitz-Zagrosek</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Gender aspects in cardiovascular pharmacology</article-title>. <source>J Cardiovasc Transl Res</source> <volume>2</volume>, <fpage>258</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr40-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okitsu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kanda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Imazeki</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yonemitsu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yokosuka</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer</article-title>. <source>Genes Cancer</source> <volume>1</volume>, <fpage>859</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr41-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olivo-Marston</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Mechanic</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Mollerup</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bowman</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Remaley</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Forman</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Skaug</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Haugen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>C. C.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women</article-title>. <source>Carcinogenesis</source> <volume>31</volume>, <fpage>1778</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr42-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinton</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Manente</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Favoni</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Mutti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib</article-title>. <source>PLoS One</source> <volume>5</volume>, <fpage>e14110</fpage>.</citation>
</ref>
<ref id="bibr43-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pressler</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sissung</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Venzon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Figg</surname>
<given-names>W. D.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Expression of OATP family members in hormone-related cancers: Potential markers of progression</article-title>. <source>PLoS One</source> <volume>6</volume>, <fpage>e20372</fpage>.</citation>
</ref>
<ref id="bibr44-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hebrok</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Cellular plasticity within the pancreas—lessons learned from development</article-title>. <source>Dev Cell</source> <volume>18</volume>, <fpage>342</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr45-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rivera</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Graeme-Cook</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Z’Graggen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rustgi</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Rattner</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Warshaw</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Fernandez-del Castillo</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>A rat model of pancreatic ductal adenocarcinoma: Targeting chemical carcinogens</article-title>. <source>Surgery</source> <volume>122</volume>, <fpage>82</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr46-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santen</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Allred</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Ardoin</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Archer</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Braunstein</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>H. G.</given-names>
</name>
<name>
<surname>Colditz</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Gambacciani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gower</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>V. W.</given-names>
</name>
<name>
<surname>Jarjour</surname>
<given-names>W. N.</given-names>
</name>
<name>
<surname>Karas</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Kleerekoper</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Manson</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pinkerton</surname>
<given-names>J. V.</given-names>
</name>
<name>
<surname>Rubinow</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Teede</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Thiboutot</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Utian</surname>
<given-names>W. H.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Postmenopausal hormone therapy: An Endocrine Society scientific statement</article-title>. <source>J Clin Endocrinol Metab</source> <volume>95</volume>, <fpage>s1</fpage>–<lpage>s66</lpage>.</citation>
</ref>
<ref id="bibr47-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teng</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G. Q.</given-names>
</name>
<name>
<surname>Diao</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma</article-title>. <source>Oncol Rep</source> <volume>23</volume>, <fpage>811</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr48-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuei</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Jeng</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Male germ cell-specific RNA binding protein RBMY: A new oncogene explaining male predominance in liver cancer</article-title>. <source>PLoS One</source> <volume>6</volume>, <fpage>e26948</fpage>.</citation>
</ref>
<ref id="bibr49-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uppstad</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Osnes</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Haugen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mollerup</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells</article-title>. <source>Lung Cancer</source> <volume>71</volume>, <fpage>264</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr50-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>W. G.</given-names>
</name>
<name>
<surname>Tilleman</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Chirieac</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hurwitz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sugarbaker</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Characteristics of malignant pleural mesothelioma in women</article-title>. <source>Ann Thorac Surg</source> <volume>90</volume>, <fpage>949</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr51-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>I. K.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Direct activation of TGF-beta1 transcription by androgen and androgen receptor complex in Huh7 human hepatoma cells and its tumor in nude mice</article-title>. <source>J Cell Biochem</source> <volume>97</volume>, <fpage>393</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr52-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Liaw</surname>
<given-names>Y. F.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma</article-title>. <source>J Natl Cancer Inst</source> <volume>92</volume>, <fpage>2023</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr53-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zender</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kubicka</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Androgen receptor and hepatocarcinogenesis: What do we learn from HCC mouse models?</article-title> <source>Gastroenterology</source> <volume>135</volume>, <fpage>738</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr54-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zenser</surname>
<given-names>T. V.</given-names>
</name>
<name>
<surname>Lakshmi</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>B. B.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>N-glucuronidation of benzidine and its metabolites: Role in bladder cancer</article-title>. <source>Drug Metab Dispos</source> <volume>26</volume>, <fpage>856</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr55-0192623312446527">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Enewold</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stojadinovic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Clifton</surname>
<given-names>G. T.</given-names>
</name>
<name>
<surname>Potter</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Peoples</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Incidence rates of exocrine and endocrine pancreatic cancers in the United States</article-title>. <source>Cancer Causes Control</source> <volume>21</volume>, <fpage>853</fpage>–<lpage>61</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>